Avidity Biosciences reports data from DMD treatment trials
Avidity Biosciences (NASDAQ:RNA) has announced new data from its clinical trials evaluating the experimental treatment del-zota for Duchenne muscular dystrophy. ...
Sunday, April 5, 2026
Tag: Avidity
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.